1
/
of
1
Zoletero (Zoledronic Acid)
Zoletero (Zoledronic Acid)
Regular price
₱7,000.00 PHP
Regular price
Sale price
₱7,000.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Zoletero (Zoledronic Acid) is a potent intravenous bisphosphonate medication designed to address serious bone and mineral disorders across oncology and non-oncology settings. This injectable therapeutic agent works by inhibiting osteoclast-mediated bone resorption, effectively stabilizing bone density and reducing the risk of skeletal complications.
In oncology, Zoletero is indicated for the management of hypercalcemia of malignancy—a life-threatening condition where cancer causes dangerously elevated blood calcium levels. It is also prescribed for prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma, helping reduce fractures, spinal cord compression, and the need for palliative radiation or surgery.
Beyond cancer care, Zoletero addresses osteoporosis in postmenopausal women and men, where it slows bone loss and reduces fracture risk. It is equally valuable in treating glucocorticoid-induced osteoporosis, a secondary bone condition that develops from prolonged corticosteroid use, and Paget's disease of bone, where abnormal bone remodeling disrupts normal architecture.
The medication requires careful patient selection and monitoring. Hypocalcemia must be corrected before initiating therapy, as Zoletero can further lower calcium levels. Patients with severe renal impairment require dose adjustment or alternative management. Those with prior hypersensitivity to zoledronic acid or other bisphosphonates should not receive this treatment. Dental evaluation is recommended prior to therapy due to the rare risk of osteonecrosis of the jaw.
Dosage is individualized based on indication, renal function, and clinical response, and must always be determined by a qualified healthcare provider. Strict medical consultation and professional supervision are essential before initiating or continuing treatment with Zoletero.
In oncology, Zoletero is indicated for the management of hypercalcemia of malignancy—a life-threatening condition where cancer causes dangerously elevated blood calcium levels. It is also prescribed for prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma, helping reduce fractures, spinal cord compression, and the need for palliative radiation or surgery.
Beyond cancer care, Zoletero addresses osteoporosis in postmenopausal women and men, where it slows bone loss and reduces fracture risk. It is equally valuable in treating glucocorticoid-induced osteoporosis, a secondary bone condition that develops from prolonged corticosteroid use, and Paget's disease of bone, where abnormal bone remodeling disrupts normal architecture.
The medication requires careful patient selection and monitoring. Hypocalcemia must be corrected before initiating therapy, as Zoletero can further lower calcium levels. Patients with severe renal impairment require dose adjustment or alternative management. Those with prior hypersensitivity to zoledronic acid or other bisphosphonates should not receive this treatment. Dental evaluation is recommended prior to therapy due to the rare risk of osteonecrosis of the jaw.
Dosage is individualized based on indication, renal function, and clinical response, and must always be determined by a qualified healthcare provider. Strict medical consultation and professional supervision are essential before initiating or continuing treatment with Zoletero.
Share
